Essais cliniques : à propos de la fourniture des médicaments expérimentaux par les promoteurs - Expérience de l'hôpital de Brabois adultes - CHU de Nancy

While the net gains for the scientific community and in particular for biomedical research are clearly established, the financial losses associated to the promoter's default in assuming their legally binding responsibilities should definitely be weighed in.